Induction of Endothelial PAS Domain Protein-1 by Hypoxia: Characterization and Comparison with Hypoxia-inducible Factor-1alpha
Overview
Authors
Affiliations
Hypoxia results in adaptive changes in the transcription of a range of genes including erythropoietin. An important mediator is hypoxia-inducible factor-1 (HIF-1), a DNA binding complex shown to contain at least two basic helix-loop-helix PAS-domain (bHLH-PAS) proteins, HIF-1alpha and aryl hydrocarbon nuclear receptor translocator (ARNT). In response to hypoxia, HIF-1alpha is activated and accumulates rapidly in the cell. Endothelial PAS domain protein 1 (EPAS-1) is a recently identified bHLH-PAS protein with 48% identity to HIF-1alpha, raising the question of its role in responses to hypoxia. We developed specific antibodies and studied expression and regulation of EPAS-1 mRNA and protein across a range of human cell lines. EPAS-1 was widely expressed, and strongly induced by hypoxia at the level of protein but not mRNA. Comparison of the effect of a range of activating and inhibitory stimuli showed striking similarities in the EPAS-1 and HIF-1alpha responses. Although major differences were observed in the abundance of EPAS-1 and HIF-1alpha in different cell types, differences in the inducible response were subtle with EPAS-1 protein being slightly more evident in normoxic and mildly hypoxic cells. Functional studies in a mutant cell line (Ka13) expressing neither HIF-1alpha nor EPAS-1 confirmed that both proteins interact with hypoxically responsive targets, but suggest target specificity with greater EPAS-1 transactivation (relative to HIF-1alpha transactivation) of the VEGF promoter than the LDH-A promoter.
Hypoxia and the endometrium: An indispensable role for HIF-1α as therapeutic strategies.
Dai W, Guo R, Na X, Jiang S, Liang J, Guo C Redox Biol. 2024; 73:103205.
PMID: 38815332 PMC: 11167393. DOI: 10.1016/j.redox.2024.103205.
Lawson H, Holt-Martyn J, Dembitz V, Kabayama Y, Wang L, Bellani A Nat Cancer. 2024; 5(6):916-937.
PMID: 38637657 PMC: 11208159. DOI: 10.1038/s43018-024-00761-w.
UBE3B promotes breast cancer progression by antagonizing HIF-2α degradation.
Wang Y, Liu X, Wang M, Wang Y, Wang S, Jin L Oncogene. 2023; 42(46):3394-3406.
PMID: 37783786 DOI: 10.1038/s41388-023-02842-z.
The SUMOylation and ubiquitination crosstalk in cancer.
Li K, Xia Y, He J, Wang J, Li J, Ye M J Cancer Res Clin Oncol. 2023; 149(17):16123-16146.
PMID: 37640846 DOI: 10.1007/s00432-023-05310-z.
Hao H, Hou Y, Li A, Niu L, Li S, He B CNS Neurosci Ther. 2023; 29(12):3802-3814.
PMID: 37334735 PMC: 10651974. DOI: 10.1111/cns.14300.